Monoclonal Antibodies Cut Ischemia-Reperfusion Injury

This article originally appeared here.
Share this content:
Monoclonal Antibodies Cut Ischemia-Reperfusion Injury
Monoclonal Antibodies Cut Ischemia-Reperfusion Injury

WEDNESDAY, Nov. 22, 2017 (HealthDay News) -- Anti-CD47 monoclonal antibody (CD47mAb) therapy reduces ischemia-reperfusion injury of renal allografts in an animal transplantation model, according to a study published online Oct. 31 in the American Journal of Transplantation.

Min Xu, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues investigated whether blockade of the CD47 signaling pathway could reduce ischemia-reperfusion injury (IRI) of renal allografts donated after cardiac death (DCD) in a porcine animal model of transplantation. Renal allografts were subjected to 30 minutes of warm ischemia and 3.5 hours of cold ischemia followed by perfusion with either a humanized CD47mAb (treatment group; n = 4) or Histidine-Tryptophan-Ketoglutarate solution (control group; n = 4).

Using in vivo imaging, the researchers found that CD47mAb-treated organs had greater and more uniform reperfusion. The treatment group had lower creatinine and blood urea nitrogen values on post-transplant days three to five compared with the control group. There was a significant decrease of acute tubular injury upon histological examination of allograft tissues in the CD47mAb-treated group versus controls. CD47mAb treatment also significantly decreased gene expression related to oxidative stress (sod-1, gpx-1, and txn) and the inflammatory response (il-2, il-6, inf-g, and tgf-b) and reduced protein levels of BAX, Caspase-3, MMP2, and MMP9.

"These data demonstrate that CD47mAb blockade decreases IRI and subsequent tissue injury in DCD renal allografts in a large animal transplant model," conclude the authors.

Several authors disclosed financial ties to biopharmaceutical companies, including Tioma Therapeutics, which provided the monoclonal antibodies.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »